BiotechTube

Risankizumab + Placebo for Risankizumab

ApprovedCompleted
0 views this week 0 watching⚡ Active
Interest: 43/100
43
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
✓
Phase 3
5
Approved
Indication / Disease

Genital Psoriasis

Conditions

Genital Psoriasis, Scalp Psoriasis

Trial Timeline

Aug 10, 2023 → Nov 28, 2025

NCT ID
NCT05969223

About Risankizumab + Placebo for Risankizumab

Risankizumab + Placebo for Risankizumab is a approved stage product being developed by AbbVie for Genital Psoriasis. The current trial status is completed. This product is registered under clinical trial identifier NCT05969223. Target conditions include Genital Psoriasis, Scalp Psoriasis.

What happened to similar drugs?

9 of 20 similar drugs in Genital Psoriasis were approved

Approved (9) Terminated (0) Active (11)
✅Famciclovir + PlaceboNovartisApproved
✅FamciclovirNovartisApproved
✅FamciclovirNovartisApproved
✅turoctocog alfaNovo NordiskApproved
✅eptacog alfa (activated) + Feiba VHNovo NordiskApproved
✅activated recombinant human factor VIINovo NordiskApproved
✅activated recombinant human factor VII + activated recombinant human factor VII + factor VIIINovo NordiskApproved

Hype Score Breakdown

Clinical
20
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (5)

NCT IDPhaseStatus
NCT05969223ApprovedCompleted
NCT03926169Phase 2Completed
NCT03398135Phase 3Active
NCT03000075Phase 2Completed
NCT02719171Phase 2Completed

Competing Products

20 competing products in Genital Psoriasis

See all competitors
ProductCompanyStageHype Score
mRNA-1608ModernaPhase 2
0
TideglusibAMO PharmaPre-clinical
20
Tideglusib + PlaceboAMO PharmaPhase 2/3
28
TideglusibAMO PharmaPhase 2/3
35
Fulvestrant + AbemaciclibEli LillyPhase 2
39
EDIT-101Editas MedicinePhase 1/2
18
Gemcitabine + liposomal doxorubicinEli LillyPhase 3
40
Tildacerfont/PlaceboSpruce BiosciencesPhase 2
17
SPR001Spruce BiosciencesPhase 2
25
SPR001Spruce BiosciencesPhase 2
25
Tildacerfont/PlaceboSpruce BiosciencesPhase 2
17
TildacerfontSpruce BiosciencesPhase 2
17
ASP2151 + PlaceboAstellas PharmaPhase 1
29
ASP2151 + valacyclovir + PlaceboAstellas PharmaPhase 2
35
Tildrakizumab 100 mg + PlaceboSun PharmaceuticalPhase 3
44
Topical NO + PlaceboKyowa KirinPhase 2
35
KW-3357Kyowa KirinPhase 1
29
Ixekizumab + PlaceboEli LillyPhase 3
40
Gemcitabine + Paclitaxel + CarboplatinEli LillyPhase 3
40
DaratumumabJohnson & JohnsonPhase 2
27